SecBot SecBot
DEFA14A ·Filed Mar 27, 2026

RARE

Ultragenyx Pharmaceutical Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed7mo ago SEC0001308179-26-000175
Proxy solicitation materials
Actionable Insight • Neutral

This is a routine administrative filing. Traders should note the upcoming annual meeting but do not need to take any immediate action based on this filing. Monitor for the actual proxy statement and annual report for any material updates.

DirectionNeutral
Confidencelow
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$19.30
T+0 close · Mar 27, 2026 · via day close
Latest settled
+51.55%
T+60 · $29.25
Vs SPY
+35.06%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 30 $19.30entry
  2. T+1 · 8mo ago +8.55%α +5.66% · $20.95
  3. T+5 · 7mo ago +19.95%α +15.65% · $23.15
  4. T+20 · 7mo ago +27.10%α +14.50% · $24.53
  5. T+60 · 5mo ago +51.55%α +35.06% · $29.25
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ultragenyx Pharmaceutical Inc. (RARE) has filed a definitive additional proxy soliciting material (DEFA14A) for its 2026 Annual Meeting. The filing is routine and contains standard voting instructions for shareholders, including a notice to vote on proposals by May 13, 2026, and information on how to access meeting materials. There is no material financial data or significant corporate action disclosed.

Key Financial Metrics

Meeting
2026-05-14

Key Facts

  • Filing is a DEFA14A, which is a definitive additional proxy soliciting material.
  • It is for the 2026 Annual Meeting of shareholders.
  • The document contains a notice to vote by May 13, 2026, and instructions on how to access the proxy statement and annual report.
  • The filing is routine and does not contain any new financial information or significant corporate announcements.

Financial Impact

No material financial impact disclosed.

Risk Factors

  • None disclosed in this filing.
  • The filing is routine and does not indicate any immediate risks.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001308179-26-000175
Document: 0001308179-26-000175-index.html0001308179-26-000175
Document: 0001308179-26-000175.txt0001308179-26-000175

Track record

22 reports on RARE

Performance horizon

8 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +48.73% at T+60 after the Apr 2, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $16.08 Now $15.90 −1.12% settles Nov 20
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $16.14 Now $15.90 −1.49% settles Nov 17
  3. Nov 3, 202613d ago 8-K Mixed 6/10 No price data
  4. Nov 3, 202613d ago Press Release Bearish 6/10 Entry $17.16 to $16.70 Now $15.90 +7.34% ▲ +2.68% +1.77% vs SPY
  5. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $16.10 to $15.43 Now $15.90 −1.24% ▼ −4.16% −1.46% vs SPY
  6. Oct 20, 202627d ago SC 13G Neutral 3/10 Entry $15.92 to $16.75 Now $15.90 −0.13% ▲ +5.21% +5.66% vs SPY
  7. Oct 19, 202628d ago 8-K Neutral 4/10 Entry $15.07 to $16.08 Now $15.90 +5.51% ▲ +6.70% +6.85% vs SPY
  8. Oct 14, 20264w ago 8-K Bullish 6/10 Entry $14.90 to $15.92 Now $15.90 +6.71% ▲ +6.85% +6.39% vs SPY
  9. Oct 7, 20265w ago 8-K Bullish 6/10 Entry $14.89 to $14.90 Now $15.90 +6.78% ▲ +0.07% +1.05% vs SPY
  10. Sep 17, 20268w ago Press Release Bullish 8/10 Entry $14.50 to $14.77 Now $15.90 +9.66% ▲ +1.86% +1.01% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens in 7h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 27, 2026